NCT05198505

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2868 Injection in Subjects With Advanced Malignant Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The TQB2868 protein in this study targeted programmed cell death protein 1 (PD-1) and transforming growth factor-β (TGF-β). The bifunctional fusion protein targets and neutralizes TGF-β in the tumor microenvironment. On the basis of inhibiting PD-1 / programmed death ligand 1 (PD-L1) pathway, T cells can restore activity, enhance immune response, and more effectively improve the effect of inhibiting tumor occurrence and development.

Conditions

• Advanced Malignant Tumor

Interventions

Type	Name	Description
DRUG	TQB2868 Injection	TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β

Timeline

• Start date: 2022-04-27
• Primary completion: 2023-06-01
• Completion: 2024-06-01
• First posted: 2022-01-20
• Last updated: 2022-05-02

Locations

3 sites across 1 country: China